In yesterday’s Wall Street session, DexCom Inc. (NASDAQ:DXCM) shares traded at $128.51, up 0.45% from the previous session.
22 analysts cover DexCom Inc. (NASDAQ:DXCM), according to research data. The consensus rating among analysts is ‘Buy’. As we calculate the median target price by taking the range between a high of $152.00 and a low of $115.00, we find $145.50. Given the previous closing price of $127.94, this indicates a potential upside of 13.73 percent. DXCM stock price is now 5.30% away from the 50-day moving average and 14.66% away from the 200-day moving average. The market capitalization of the company currently stands at $49.22B.
Top 5 Artificial Intelligence Stocks to Buy for 2024
By now, you're well aware of the artificial intelligence boom. You know Big Tech has been investing billions of dollars into it.
According to Next Move Strategy Consulting, the AI market – currently valued at about $100 billion – cold grow twenty-fold by 2030 to more than $2 trillion. That means you may want to strongly consider these top AI stocks. Get our free report, "Top 5 AI Stocks to Buy in 2024."
Click here to automatically get the our FREE Report & Special Offer "5 Best AI Stocks to Invest In"
Sponsored
The stock has received a hold rating from 3 analysts and a buy rating from 17. Brokers who have rated the stock have averaged $142.32 as their price target over the next twelve months.
In other news, Pacelli Steven Robert, EVP Managing Director Dexcom V sold 412 shares of the company’s stock on Jun 23. The stock was sold for $51,879 at an average price of $125.92. Upon completion of the transaction, the EVP Managing Director Dexcom V now directly owns 131,862 shares in the company, valued at $16.95 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Jun 15, SVP Chief Information Officer Selvaraj Shelly Ramasamy sold 2,115 shares of the business’s stock. A total of $274,953 was realized by selling the stock at an average price of $130.00. This leaves the insider owning 50,390 shares of the company worth $6.48 million. Insiders disposed of 464,523 shares of company stock worth roughly $59.7 million over the past 1 year. A total of 0.10% of the company’s stock is owned by insiders.
There have been several recent changes in the stakes of large investors in DXCM stock. A new stake in DexCom Inc. shares was purchased by REDMILE GROUP, LLC during the first quarter worth $43,186,000. QUBE RESEARCH & TECHNOLOGIES LTD invested $27,703,000 in shares of DXCM during the first quarter. In the first quarter, ADAMS DIVERSIFIED EQUITY FUND, INC. acquired a new stake in DexCom Inc. valued at approximately $25,054,000. SUMMIT PARTNERS PUBLIC ASSET MANAGEMENT, LLC acquired a new stake in DXCM for approximately $16,249,000. VOLORIDGE INVESTMENT MANAGEMENT, LLC purchased a new stake in DXCM valued at around $10,493,000 in the second quarter. In total, there are 1,324 active investors with 98.80% ownership of the company’s stock.
On Friday morning DexCom Inc. (NASDAQ: DXCM) stock kicked off with the opening price of $129.76. During the past 12 months, DexCom Inc. has had a low of $73.71 and a high of $134.14. As of last week, the company has a debt-to-equity ratio of 0.91, a current ratio of 2.00, and a quick ratio of 1.80. According to the stock market information, the enterprise value for the company is $49.17B, which is based on a 186.25 price-to-earnings ratio, a 6.25 price-to-earnings-growth ratio, and a beta of 1.15. The fifty day moving average price for DXCM is $122.13 and a two-hundred day moving average price translates $112.27 for the stock.
The latest earnings results from DexCom Inc. (NASDAQ: DXCM) was released for Mar, 2023. According to the Medical Devices Company, earnings per share came in at $0.17, beating analysts’ expectations of $0.15 by 0.02. This compares to $0.23 EPS in the same period last year. The net profit margin was 9.70% and return on equity was 13.90% for DXCM. The company reported revenue of $741.5 million for the quarter, compared to $628.8 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 17.92 percent. For the current quarter, analysts expect DXCM to generate $842.12M in revenue.
DexCom Inc.(DXCM) Company Profile
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices for specific and permitted use cases, including non-medical device applications, medical device data analysis, integrated continuous glucose monitoring systems (iCGM) secondary display alarms, active patient monitoring, and treatment decisions; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
